**Abstract**

**Objective:** Although lamotrigine has been widely used in bipolar disorders in many countries, in Japan, it was approved for bipolar disorders at July 2011. This study was conducted to investigate the long term efficacy and tolerability of lamotrigine.

**Method:** The subjects were 91 patients who were diagnosed as bipolar disorder(type1:n=40, type2;n=51) and treated with lamotrigine from Jan 2012 to Aug 2014 in our psychiatric hospital. We retrospectively investigated the clinical efficacy, safety and 52-week-continuation rate of lamotrigine, and also the relating clinical factors such as age, gender, diagnosis(type1 or 2), clinical state(depressive/manic/mixed), dose, concomitant psychotropic medication. We evaluated the efficacy as clinical global impression of improvement (CGI-I). Patients with a score of minimally (3), much (2) or very much improved (1) were considered as responders.

**Results:** Although the response rate of lamotirigine was 72.2 % for the patients with depressive and mixed state, The patients with type 2 bipolar disorders showed higher response rate than that with type 1(78.4% vs 60.0%). Main side effect was skin rash (16.5 %). The total 52-week continuation rate was 58.1 %. The main cause of discontinuation was mucocutaneous symptoms at early phase (almost within 8 week) and following cause was lack of insight. The continuation rate in the patients with depressive and euthymic state was higher than those with mixed and manic state(66.2% vs 21.4%).

**Conclusion:** Lamotrigine was effective and well tolerable, especially for type 2 bipolar disorder. The management of the side effect as mucocutaneous symptoms and psychoeducation might be necessary to increase the long term continuation rate.
